


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled):

2. (Cancelled):

3. (Currently Amended): A diacylhydrazine compound ~~according to claim 1~~, selected from the compounds of formula II,



wherein

Ar¹ is phenyl,

~~Ar¹, Ar² are each independently selected from is an aromatic hydrocarbon group hydrocarbons containing 6 to 14 carbon atoms, or an and ethylenical unsaturated or aromatic heterocyclic group residues containing 3 to 10 carbon atoms and one, two, or three heteroatoms, wherein said heteroatoms are in each case independently selected from N, O, or and S,~~

~~E, G, M, Q and U are each independently a carbon atom selected from carbon atoms and nitrogen atoms, with the proviso that one or more of E, G, M, Q and U are carbon atoms and that X is bonded to a carbon atom,~~

~~R⁸, R⁹ and R¹⁰ are each independently selected from H, A, OA, cycloalkyl having comprising 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)ₙCN, (CH₂)ₙNR¹¹R¹², (CH₂)ₙO(CH₂)ₖNR¹¹R¹²,~~

$(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$, $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$,
 $(CH_2)_nCOOR^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$,
 $(CH_2)_nNR^8CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$,
 $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $CH=N-OA$,
 $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$,
 $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$,
 $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $(CH_2)_nN(R^{11})C(R^{13})HCOR^{11}$,
 $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{11}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$,
 $CH=CHCOOR^{13}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$,
 $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{13})COOR^{14}$, $(CH_2)_nN(CONH_2)COOR^{13}$,
 $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$,
 $(CH_2)_nN(CH_2CONH_2)COOR^{13}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
 $(CH_2)_nCHR^{13}COR^{14}$, $(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$,
 $(CH_2)_nOCN$, or and $(CH_2)_nNCO$,

R^{11} , R^{12} are each independently selected from H, A, $(CH_2)_mAr^3$ or and $(CH_2)_mHet$, or

in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-, 6- or 7- membered heterocyclyl which optionally contains 1 or 2 additional hetero atoms, selected from which in each case is N, O or and S,

R^{13} , R^{14} are each independently selected from H, Hal, A, $(CH_2)_mAr^4$ or and $(CH_2)_mHet$,

A is selected from alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy, alkoxyalkyl or and saturated heterocyclyl,

Ar^3 , Ar^4 are each, independently from one another, an aromatic hydrocarbon residue having residues comprising 5 to 12 carbon atoms which is are optionally substituted by one or more substituents, wherein said substituents are in each case selected from A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$,

$\text{NR}^{15}\text{COR}^{16}$, $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{16}\text{SO}_2\text{A}$, COR^{15} , $\text{SO}_2\text{R}^{15}\text{R}^{16}$, $\text{S(O)}_u\text{A}$ or and OOCR^{15} ,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, wherein said substituents are in each case selected from A, Hal, NO_2 , CN, OR¹⁵, $\text{NR}^{15}\text{R}^{16}$, COOR¹⁵, CONR¹⁵R¹⁶, $\text{NR}^{15}\text{COR}^{16}$, $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{16}\text{SO}_2\text{A}$, COR^{15} , $\text{SO}_2\text{R}^{15}\text{R}^{16}$, $\text{S(O)}_u\text{A}$, or and OOCR^{15} ,

R^{15} , R^{16} are each, independently, selected from H, A, or and $(\text{CH}_2)_m\text{Ar}^6$,

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents, wherein said substituents are in each case selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 , or and CF_3 ,

k, n and m are each, independently of one another, 0, 1, 2, 3, 4, or 5;

X is represents a bond or is $(\text{CR}^{11}\text{R}^{12})_h$, or $(\text{CHR}^{11})_h\text{-Q-}(\text{CHR}^{12})_i$,

Q is selected from T, $\text{CH}^{15}\text{H}^{16}$, $(\text{CHal}_2)_j$, $(\text{O-CHR}^{18})_j$, $(\text{CHR}^{18}\text{-O})_j$, $\text{CR}^{18}=\text{CR}^{19}$, $(\text{O-CHR}^{18}\text{CHR}^{19})_j$, $\text{CHR}^{18}\text{CHR}^{19}\text{-O})_j$, C=O, C=S, C=NR¹⁵, $\text{CH}(\text{OR}^{15})$, $\text{C}(\text{OR}^{15})(\text{OR}^{20})$, C(=O)O, OC(=O), OC(=O)O, C(=)N(R¹⁵), $\text{N}(\text{R}^{15})\text{C}(=\text{O})$, OC(=O)N(R¹⁵), $\text{N}(\text{R}^{15})\text{C}(=\text{O})\text{O}$, CH=N-O, CH=N-NR¹⁵, OC(O)NR^{15} , $\text{NR}^{15}\text{C(O)O}$, S=O, SO_2 , $\text{SO}_2\text{NR}^{15}$, or and $\text{NR}^{15}\text{SO}_2$,

T is selected from O, S, or N-R^{15} ,

h, i are each, independently from each other, 0, 1, 2, 3, 4, 5 or 6,

j is 1, 2, 3, 4, 5 or 6,

Y is O, selected from O/S, NR²¹, C(R²²)NO₂, C(R²²)CN and C(CN)₂,

O/S is O or S,

R²⁴ is independently selected from H, Hal, A, (CH₂)_mAr⁴ and (CH₂)_mHet,

R²² is independently selected from H, A, (CH₂)_mAr³ and (CH₂)_mHet,

p, r are each, independently from one another, 0, 1, 2, 3, 4 or 5,


q is 0, 1, 2, 3 or 4,






u is 0, 1, 2 or 3, and






Hal is in each case independently selected from F, Cl, Br and I,






and the pharmaceutically acceptable derivatives, salts and solvates thereof.






4. (Currently Amended): A diacylhydrazine compound according to claim 3, selected from the compounds of Formulas formula IIa, IIb, IIc, IId, IIe, IIf, IIg, IIh, IIi, IIj, IIk, IIl, IIm, IIn, IIo, IIp, IIq, IIr, IIu, IIv, IIw and IIx,
















and the pharmaceutically acceptable derivatives, salts and solvates thereof.

5. (Currently Amended): A diacylhydrazine compound according to claim 3, wherein

~~E, G, M, U and Q are each carbon atoms,~~

X is O or a bond,

~~Y~~ is O,

~~Ar¹~~ is phenyl or indolyl,

Ar² is pyridinyl,

R⁸ is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, CHal₃ or OCHal₃,

R¹⁰ is H or CONCH₃,

p is 0, 1, 2 or 3,

q is 0, and








r is 1.







6. (Previously Presented): A diacylhydrazine compound according to claim 5, wherein X is O and R¹⁰ is CONCH₃.






7. (Previously Presented): A diacylhydrazine compound according to claim 5, wherein X is a bond and R¹⁰ is H.






8. (Currently Amended): A diacylhydrazine compound according to claim 3, wherein ~~E, G, M, U and Q are each carbon atoms~~, X is O, S or NR¹⁵, and Y is O.







9. (Currently Amended): A diacylhydrazine compound according to claim 3, ~~selected from the compounds (1) to (224) of table 1 and compounds (225) to (384) of table 2, wherein said compound is a compound of the Formula A-CO-NH-NH-CO-B and A and B are selected from the following sets (1), (2), and (5)-(224), wherein in each set the group for A is listed first and the group for B is listed second:~~




































































































































































2.62














2

































































































and pharmaceutically acceptable derivatives, salts and solvates thereof.

10. (Cancelled):

11. (Cancelled):

12. (Cancelled):

13. (Withdrawn; Previously Presented): A pharmaceutical composition comprising one or more compounds according to claim 1 and one or more additional compounds.

14. (Previously Presented): A pharmaceutical composition according to claim 13, wherein said one or more additional compounds are selected from physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.

15. (Withdrawn; Previously Presented): A process for the manufacture of a pharmaceutical composition, comprising processing by mechanical means one or more compounds according to claim 1 and one or more compounds selected from carriers, excipients, auxiliaries and pharmaceutical active ingredients, other than the compounds according to claim 1, into a pharmaceutical composition that is suitable as dosage form for application and/or administration to a patient.

16. (Cancelled):

17. (Cancelled):

18. (Cancelled):

19. (Withdrawn; Currently Amended): A method for the treatment ~~or prophylaxis~~ of a disorder caused, mediated and/or propagated by raf-kinases, said method comprising administering to a patient in need thereof an effective amount of a kinase inhibitor compound according to claim 1.

20. (Withdrawn; Currently Amended): A method according to claim 19, wherein said disorder is ~~a selected from~~ hyperproliferative disorder and nonhyperproliferative disorders.

21. (Withdrawn; Previously Presented): A method according to claim 19, wherein said disorder is cancer.

22. (Withdrawn; Previously Presented): A method according to claim 19, wherein said disorder is noncancerous.

23. (Withdrawn; Currently Amended): A method according to claim 22, wherein said disorder is ~~selected from~~ psoriasis, arthritis, inflammation, endometriosis, scarring, Helicobacter pylori infection, Influenza A, benign prostatic hyperplasia, an immunological disease, an autoimmune disease, or an immunodeficiency disease ~~immunological diseases, autoimmune diseases, and immunodeficiency diseases~~.

24. (Withdrawn; Currently Amended): A method according to claim 19, wherein said disorder is ~~selected from~~ melanoma, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, ovary cancer, uterine cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukemia, or and acute leukemia.

25. (Withdrawn; Currently Amended): A method according to claim 19, wherein said disorder is ~~selected from~~ arthritis, restenosis, a fibrotic disorder disorders, a mesangial cell proliferative disorder disorders, diabetic nephropathy, malignant nephrosclerosis, a thrombotic microangiopathy syndrome syndromes, organ transplant rejection, glomerulopathies, a metabolic disorder disorders, inflammation, a solid tumor tumors, rheumatic arthritis, diabetic retinopathy, and or a neurodegenerative disease diseases.

26. (Withdrawn; Currently Amended): A method according to claim 19, wherein said disorder is ~~selected from~~ rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease, and or an angiogenesis disorder disorders.

27. (Withdrawn; Currently Amended): A method according to claim 19, wherein said compound is a raf-kinase inhibitor.

28. (Withdrawn; Currently Amended): A method according to claim 27, wherein the raf-kinase is ~~selected from~~ A-Raf, B-Raf, or and c-Raf1.

29. (Cancelled):


30. (Withdrawn; Previously Presented): A method according to claim 19, wherein the one or more compounds are administered as a pharmaceutical composition.

31. (Withdrawn; Previously Presented): A method according to claim 19, wherein the disorder is cancerous cell growth mediated by raf kinase.


32. (Cancelled):

33. (Withdrawn; Currently Amended): A method for preparing a compound according to claim 3 2, said process comprising:

reacting a compound of formula III



with a compound of IV,




wherein

LG₁ is a leaving group,

and optionally

isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

34. (Withdrawn; Previously Presented): A compound according to formula III,



wherein

Ar¹ is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one, two, or three hetero atoms, independently selected from N, O and S,

R^8 is H, A, OA, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$, $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^8CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$,

$(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$,
 $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $(CH_2)_nN(R^{11})C(R^{13})HCOR^{11}$,
 $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{11}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{13}$,
 $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{13})COOR^{14}$,
 $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$,
 $(CH_2)_nN(CH_2CONH_2)COOR^{13}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$,
 $(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$,

R^{11} , R^{12} are each independently selected from H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocyclyl which optionally contains 1 or 2 additional hetero atoms, selected from N, O and S,

R^{13} , R^{14} are each independently selected from H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

A is selected from alkyl, alkenyl, cycloalkyl, alkylene cycloalkyl, alkoxy, alkoxyalkyl and saturated heterocyclyl,

Ar^3 , Ar^4 are each independently from one another aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15} , $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15} , $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15} , R^{16} are independently selected from H, A, and $(CH_2)_mAr^6$,

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by

one or more substituents selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂ and CF₃,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

Y is selected from O/S, NR²¹, C(R²²)-NO₂, C(R²²)-CN and C(CN)₂,

O/S is O or S,


R²¹ is independently selected from H, Hal, A, (CH₂)_mAr⁴ and (CH₂)_mHet,

R²² is independently selected from H, A, (CH₂)_mAr³ and (CH₂)_mHet,

u is 0, 1, 2 or 3, and

Hal is independently selected from F, Cl, Br and I.

35. (Withdrawn; Previously Presented): A compound according to formula IV,



wherein

LG₁ is a leaving group selected from OR²⁵,

R²⁵ is selected from unsubstituted or substituted aromatic residues, unsubstituted or substituted heteroaromatic residues and (O)₂S-R²⁶,

R²⁶ is selected from unsubstituted or substituted aromatic residues and unsubstituted

or substituted alkyl residues,

Ar^2 is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one, two, or three hetero atoms, independently selected from N, O and S,

E, G, M, Q and U are each independently selected from carbon atoms and nitrogen atoms, with the proviso that one or more of E, G, M, Q and U are carbon atoms and that X is bonded to a carbon atom,

R^9 and R^{10} are each independently selected from H, A, OA, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $\text{CH}(\text{Hal})_2$, $\text{C}(\text{Hal})_3$, NO_2 , $(\text{CH}_2)_n\text{CN}$, $(\text{CH}_2)_n\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{OR}^{11}$, $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{OR}^{12}$, $(\text{CH}_2)_n\text{COOR}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$, $(\text{CH}_2)_n\text{NR}^8\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{S}(\text{O})_u\text{R}^{13}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{SR}^{11}$, $\text{CH}=\text{N-OA}$, $\text{CH}_2\text{CH}=\text{N-OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH}=\text{N-R}^{11}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOR}^{11}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{12})\text{CH}_2\text{COOR}^{11}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCOOR}^{13}$, $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{COOR}^{13})\text{COOR}^{14}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^{13})\text{COOR}^{14}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$, $(\text{CH}_2)_n\text{OCN}$ and $(\text{CH}_2)_n\text{NCO}$,

R^{11} , R^{12} are each independently selected from H, A, $(\text{CH}_2)_m\text{Ar}^3$ and $(\text{CH}_2)_m\text{Het}$, or in $\text{NR}^{11}\text{R}^{12}$, R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocyclyl which optionally contains 1 or 2 additional hetero atoms, selected from N, O and S,

R^{13} , R^{14} are each independently selected from H, Hal, A, $(\text{CH}_2)_m\text{Ar}^4$ and $(\text{CH}_2)_m\text{Het}$,

A is selected from alkyl, alkenyl, cycloalkyl, alkylene cycloalkyl, alkoxy, alkoxyalkyl and saturated heterocyclyl,

Ar³, Ar⁴ are each independently from one another aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and OOCR¹⁵,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and OOCR¹⁵,

R¹⁵, R¹⁶ are independently selected from H, A, and (CH₂)_mAr⁶,

Ar⁶ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂ and CF₃,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X represents a bond or is (CR¹¹R¹²)_h, or (CHR¹¹)_h-Q-(CHR¹²)_i,

Q is selected from T, CH¹⁵H¹⁶, (CHal₂)_j, (O-CHR¹⁸)_j, (CHR¹⁸-O)_j, CR¹⁸=CR¹⁹, (O-CHR¹⁸CHR¹⁹)_j, CHR¹⁸CHR¹⁹-O)_j, C=O, C=S, C=NR¹⁵, CH(OR¹⁵), C(OR¹⁵)(OR²⁰), C(=O)O, OC(=O), OC(=O)O, C(=)N(R¹⁵), N(R¹⁵)C(=O), OC(=O)N(R¹⁵), N(R¹⁵)C(=O)O, CH=N-O, CH=N-NR¹⁵, OC(O)NR¹⁵, NR¹⁵C(O)O, S=O, SO₂, SO₂NR¹⁵ and NR¹⁵SO₂,

T is selected from O, S, N-R¹⁵,

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6,

j is 1, 2, 3, 4, 5 or 6,

Y is selected from O/S, NR²¹, C(R²²)-NO₂, C(R²²)-CN and C(CN)₂,

O/S is O or S,

R²¹ is independently selected from H, Hal, A, (CH₂)_mAr⁴ and (CH₂)_mHet,

R²² is independently selected from H, A, (CH₂)_mAr³ and (CH₂)_mHet,

q is 0, 1, 2, 3 or 4,

u is 0, 1, 2 or 3, and

Hal is independently selected from F, Cl, Br and I.

36. (Cancelled):

37. (Currently Amended): A compound according to claim 3, wherein Ar⁴ is phenyl, pyridinyl, pyrimidyl, chinolinyl, isochinolinyl, thiophenyl, thiadiazolyl, indolyl, benzothiadiazolyl, benzotriazolyl, benzodioxolyl, oxazolyl, isoxazolyl, pyrazolyl or imidazolyl,

Ar² is phenyl, pyridinyl, pyrazolyl, pyrimidyl, chinolinyl, isochinolinyl, thiophenyl, thiadiazolyl, benzothiadiazolyl, oxazolyl, isoxazolyl, pyrazolyl and imidazolyl, and

Ar³ to Ar⁶ are each, independently from one another, phenyl, naphthyl or biphenyl, which in each case in unsubstituted or substituted by one or more substituents, selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and OOCR¹⁵.

38. (Previously Presented): A compound according to claim 3, wherein Het is 1-

piperidyl, 1-piperazyl, 1-(4-methyl)-piperazyl, 4-methylpiperazin-1-yl amine, 4-morpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)-pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)-imidazolidinyl, thiophen-2-yl, thiophen-3-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, chinolinyl, isochinolinyl, 2-pyridazyl, 4-pyridazyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 2-pyrazinyl, or 3-pyrazinyl, which in each case is unsubstituted or substituted by A, CN and Hal.

39. (Currently Amended): A compound according to claim 3, wherein

~~E, G, M, Q, U are carbon atoms,~~

R^9 is H,

Ar^2 is phenyl, pyridinyl or pyrrolyl,

R^{10} is H or $CONCH_3$,

r is 1, and

X is O or a bond.

40. (Currently Amended): A compound according to claim 3, wherein

Ar^4 is phenyl,

R^8 is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, $CHal_3$ or $OCHal_3$,

p is 1 or 2,

~~E, G, M, Q, U are carbon atoms,~~

R^9 is H,

Ar^2 is phenyl, pyridinyl or pyrrolyl,

R^{10} is H or $CONCH_3$,

r is 1, and

X is O or a bond.

41. (Currently Amended): A compound according to claim 3, wherein

Ar^4 is phenyl,

R^8 is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy,

ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, CHal₃ or OCHal₃,

p is 1 or 2,

~~E, G, M, Q, U are carbon atoms,~~

R⁹ is H,

Ar² is phenyl, pyridinyl or pyrrolyl,

R¹⁰ is H or CONCH₃,

r is 1, and

X is O.

42. (Currently Amended): A compound according to claim 3, wherein

Ar¹ is phenyl,

R⁸ is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, CHal₃ or OCHal₃,

p is 1 or 2,

~~E, G, M, Q, U are carbon atoms,~~

R⁹ is H,

Ar² is phenyl or pyridinyl,

R¹⁰ is H or CONCH₃, where when Ar² is pyridinyl, R¹⁰ is bonded in a vicinal position to the nitrogen atom of the pyridinyl residue,

r is 1, and

X is O.

43. (Cancelled):

44. (Cancelled):

45. (Cancelled):


46. (Cancelled):




47. (Previously Presented): A compound according to claim 3, wherein (R⁸)_p-Ar¹ is 3-acetyl-phenyl, 4-acetyl-phenyl, 2-bromo-phenyl, 3-bromo-phenyl, 4-bromo-phenyl, 4-




bromo-2-chloro-phenyl, 4-bromo-3-methyl-phenyl, 4-bromo-3-trifluoromethyl-phenyl, 2-chloro-phenyl, 2-chloro-4-trifluoromethyl-phenyl, 2-chloro-5-trifluoromethyl-phenyl, 3-chloro-phenyl, 3-chloro-4-methyl-phenyl, 3-chloro-4-methoxy-phenyl, 3-chloro-4-methoxy-phenyl, 4-chloro-phenyl, 4-chloro-2-trifluoromethyl-phenyl, 4-chloro-3-trifluoromethyl-phenyl, 4-chloro-2-methyl-phenyl, 5-chloro-2-methyl-phenyl, 5-chloro-2-methoxy-phenyl, 2,3-dichloro-phenyl, 2,4-dichloro-phenyl, 2,5-dichloro-phenyl, 3,4-dichloro-phenyl, 3,5-dichloro-phenyl, 2,4,5-trichloro-phenyl, 4-fluoro-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 4-ethoxy-phenyl, 2-methoxy-phenyl, 2-methoxy-5-trifluoromethyl-phenyl, 4-methoxy-phenyl, 2,5-dimethoxy-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 3-trifluoromethoxy-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 3,5-bis-trifluoromethyl-phenyl, 3-methoxy-phenyl, 3-methylsulfanyl-phenyl, 4-methylsulfanyl-phenyl, o-tolyl (2-methyl-phenyl), m-tolyl (3-methyl-phenyl), p-tolyl (4-methyl-phenyl), 2,3-dimethyl-phenyl, 2,3-dimethyl-phenyl, 2,5-dimethyl-phenyl, 3,4-dimethyl-phenyl, 3,5-dimethyl-phenyl, 2-ethyl-phenyl, 3-ethyl-phenyl, 4-ethyl-phenyl, 4-isopropyl-phenyl, 4-n-butyl-phenyl, 4-tert-butyl-phenyl, 4-n-butoxy-phenyl, or 4-tert.-butoxy-phenyl.




48. (Withdrawn; New): A method according to claim 19, wherein said disorder is a nonhyperproliferative disorders.




49. (New): A compound according to claim 3, wherein said compound is:

































































































































































































































or



and pharmaceutically acceptable salts and solvates thereof.

50. (New): A compound according to claim 9, wherein said compound is a compound of the Formula A-CO-NH-NH-CO-B in which A and B are selected from sets (1), (2), and (5)-(224), or is a pharmaceutically acceptable salt thereof

51. (New): A compound according to claim 3, wherein said compound is of Formula II or is a pharmaceutically acceptable salt thereof